網頁

醫藥 - HMS BBQ 8/20 中美健康峰會 9/15

本周日年度 BBQ 报名火热进行中,另有精彩活动等你来


哈佛大学医学院华人专家学者联合会2017年度BBQ报名火热进行中!就在这个周日,欲购从速!

习习微风,清凉一夏,在这样一个凉爽的夏末秋初,哈佛大学医学院华人专家学者联合会(HMS-CSSA)一年一度的BBQ盛会又将如期举行。几百名华人专家学者即将齐聚波士顿阿森纳公园,轻松愉快地学术交流和畅谈人生。学术不只有实验室的埋首奋进,更是有美食和远方,精彩的游戏和活动,快快行动报名吧!

为了让大家放下矜持,增进了解,认识新朋友,今年我们特别为大家准备精心策划了丢沙包比赛和Bingo Game;此外还为大家准备了棋牌,球类游戏选项,内容丰富,欢乐多多~

丢沙包比赛,你要不要施展下身手,赢得奖品呀? 


你想不想认识新朋友,探寻这些问题的答案呀?
- 谁代表HMSCSSA参加了去年的波士顿龙舟赛?
- 谁曾经在我们HMSCSSA讲座活动上担任speaker?
- 谁在longwood region工作了五年以上? 
- 谁是刚来波士顿不到一年的新朋友?


精彩不容错过,心动不如行动,赶紧注册报名吧!

时间:8月20日(周日)中午12点 - 下午4点。
地点:Arsenal Park, 485 Arsenal St, Watertown, MA 02472
交通方式:公交 70/70A 路至 Arsenal Mall 站;或选择Uber拼车,从HMS出发的话约需20分钟,4人共约15-20美元(随不同出发时间可能有变化)。自驾的话Arsenal Park / Arsenal Mall 有足够免费停车位。
报名费: 网上注册每人15美元(8月19日前),小孩免费;现场报名每人20美元。
报名链接:https://www.eventbrite.com/e/hms-cssa2017bbq-tickets-36791556536

(扫描二维码,即可跳转报名链接)

去年的活动盛况

大家吃得high,聊得high!

HMS-CSSA 2016年度BBQ大合影

HMS-CSSA invites you to join our annual summer BBQ. Let's leave our work and science behind us for one day. It is time to enjoy the nice food and fresh air in Arsenal Park and get to know more Chinese scholars and students. You are welcome to bring your family and friends.

When: Sunday, Aug 20th, 2017, 12 noon to 4 pm.
Where: Arsenal Park, 485 Arsenal St, Watertown, MA 02472.
Transit: MBTA Route 70/70A to Arsenal Park; or share an Uber, about 20 min & $15-20 for 4 if depart from HMS (may differ with different departure time) . For driving, there are enough free parking lots at Arsenal Park/Arsenal Mall.
Fee: $15 per person (online before Aug 19th). Kids free. $20 onsite.
Link: https://www.eventbrite.com/e/hms-cssa2017bbq-tickets-36791556536
    (You can also click "Read more" at the end of this article, or long press to identify the above QR code.)

Activities: barbecue, poker card game, soccer, volleyball, basketball, tennis etc.

Dear CSSA members and friends,

HMS-CSSA invites you to join our summer BBQ on Aug 20th Sunday 2017, 12pm-4pm. Let us leave our work and science behind us for one day. It is time to enjoy nice food and fresh air in Arsenal Park and get to know more fellow Chinese scholars and students. You are welcome to bring you family and friends.

When: Sunday, Aug. 20th 2017 12:00pm to 4:00.
Where: Arsenal Park, 485 Arsenal St. Watertown, MA 02472.
Fee: $ 15 online before Aug. 19th. Kids free. $20 onsite.
Activities:
– Barbecue, porker card game, soccer, volleyball, basketball, tennis et al.

link: https://www.eventbrite.com/e/hms-cssa2017bbq-tickets-36791556536

Or scan the QR code


习习微风,清凉一夏,在这样一个凉爽的夏末秋初,哈佛大学医学院华人专家学者联合会(HMS-CSSA)一年一度的BBQ盛会又将如期举行。几百名华人专家学者即将齐聚波士顿阿森纳公园,松愉快地学术交流和畅谈人生。学术不只有实验室的埋首奋进,更是有美食和远方,还在等什么,快来加入我们吧!

时间:8月20日(周日)12pm-4pm。
地点:Arsenal公园(485 Arsenal St. Watertown, MA 02472)。
报名费: 网上注册每人 $15 (8月19日前),小孩免费;现场报名每人 $20。
报名链接:https://www.eventbrite.com/e/hms-cssa2017bbq-tickets-36791556536

活动内容:
– 烧烤、扑克、足球、排球、篮球、网球等

Cheers,
HMS CSSA
http://hms-cssa.org/
.
AUGUST AT-A-GLANCE
  • YHIF2017 Boston competition is rounded off
  • The 7th U.S.-China Health Summit is coming on September 15

YHIF2017 Achieved a Great Success!

Young Health Innovators Forum (YHIF) held its 2017 Boston competition on August 5. From among 62 applicants, we selected 12 as U.S. semi-finalists to pitch their ideas. Each team presented innovative solutions to unmet needs in today’s fast-growing healthcare market, impressing our judges and the audience with how latest technologies can advance healthcare. Nonspec, MobioSense, Z Imaging and XenoTherapeutics became U.S. finalists and are invited to the final round of YHIF2017 in Beijing.
Click here to learn more about YHIF2017 teams and their innovative ideas! 

“Our minds are challenged yet inspired. We learned so much from the amazing young people this afternoon! I’d like to quote Dr. Gross, a Nobel Laureate: ‘The more we know, the more we are aware of what we know not.’”
--Olivia Ho Cheng, Board member of the U.S.-China Health Summit
The 7th U.S.-China Health Summit is Coming in September!

Themed “Megatrends in Health and Healthcare,” the 7th U.S.-China Health Summit will discuss: 1) the changing world and emerging health challenges; 2) megatrends in health and medical sciences and technology; and 3) megatrends in healthcare service innovation.

Highlighted speakers and their speech topics include: 
Yuanli Liu
Dean, PUMC School of Public Health
Speech Topic: “Public Health Achievements and NCD Challenges in China”
Donald Ingber
Funding Director, Harvard Wyss Institute 
Speech Topic: “Breakthrough Discoveries Cannot Change the World If They Do Not Leave the Lab”
David Blumenthal
President, Commonwealth Fund
Speech Topic: “ObamaCare, TrumpCare, and the Future of U.S. Healthcare” 
Xuetao Cao
President, PUMC
Speech Topic: “Achievements and Challenges in Biomedical Research and Medical Education in China and in PUMC”

More speakers and speech topics are detailed on our website.
We invite you to attend the 7th U.S.-China Health Summit Boston Part. Tickets are available on Eventbrite on a first come, first served basis, and we are offering early bird discounts until August 21.
Register for the 7th U.S.-China Health Summit right now!

About U.S.-China Health Summit
Since inaugurated in 2011, U.S.-China Health Summit is dedicated to the advancement of global health by promoting the exchange of knowledge, ideas, and experiences of healthcare leaders from the U.S., China, and other countries through high-level strategic dialogues, leadership development programs, and applied research. Click here to learn more about us.
Facebook
Facebook
Twitter
Twitter
LinkedIn
LinkedIn
Website
Website
Copyright © 2017 U.S.-China Health Summit. All rights reserved.
View this email in your browser | update your preferences or unsubscribe from this list
哈佛医学院中医药论坛

Traditional Chinese Medicine Forum-HMS
Time: 9:00am-6:00pm Sunday August 6, 2017
Place: Harvard Medical School, McLean Hospital, 115 Mill Street, Belmont,
MA 02478 FRANCIS de MARNEFFE (cafeteria)
Parking: Free 
CEUs (Continue Education Credit): 9 credits
Fee (lunch included): 
Need 9 CEU Credits: $130 for MSCM members; $180 for non-members
Free for Dr. Lee’s group, Harvard Faculty/Fellow (Please contact us, reservation needed)
Sponsored: Massachusetts Society of Chinese Medicine (MSCM)
Alternative Medicine Center, McLean Hospital, HMS
Program
9:00-9:15am Registration
9:15-12:30pm “针灸治疗花粉过敏症临床观察及特效针法演示”
Acupuncture for the treatment of seasonal allergies 
& Special techniques Demo
12:30-2:00pm Lunch & discussion
2:00pm-6:00pm “常用针刺手法实际操作技巧临床应用研究”
Clinical use of acupuncture techniques and Demo
Speaker: 纽约著名的中医专家林榕生博士, Dr. Rongsheng Lin
Contact 
Call Dr. Li 617 323 7809 or 
Email:Johnzhang999@gmail.com
一 简介: 林榕生: 纽约著名中医专家,中医针灸博士,主任医师,现为世界中医药学会联合会副主席、国际中医药专业高级技术职称评审委员会委员、世中联骨伤科、外治方法研究及穴位埋线等专业委员会副会长;世界针灸学会联合会执委、世针联中医针灸传承工作委员会副主任委员、美国中医药学会董事局主席,福建中医药大学美国校友会会长,美国大纽约中医针灸学会总顾问、全美华裔中医组织联合会副主席,国际中医药联盟美容养生专家委员会副主任委员,福建中医药大学等多所大学以及中国全军针灸培训中心客座教授,联合国教科文组织人类非物质文化遗产代表作名录中医针灸代表性传承人张缙教授亲传入室弟子。
二,上午讨论的题目:“针灸治疗花粉过敏症临床观察及特效针法演示”
三,下午讨论的题目:“常用针刺手法实常用针刺手法实际操作技巧临床应用研究”






DESCRIPTION

Boston Taiwanese Biotechnology Symposium is held by Boston Taiwanese Biotechnology Association (BTBA), a non-profit organization established by Taiwanese professionals in biology-related fields in 2012 in Boston. We strive to bridge the academics and industry gap in the U.S. and Taiwan and to meet the needs of professionals in biology-related fields.
This year, we are honored to introduce Dr. Lily Y. Jan (Professor of UCSF; member of National Academy of Sciences and Academia Sinica) and Dr. James C. Liao (President of Academia Sinica; member of National Academy of Sciences and Academia Sinica) as our keynote speakers.
Highlights of our program include:
  • Panelists from both academia and industry to discuss the latest research, potential applications, and clinical development of “CRISPR technology” and “Immunotherapy”.
  • A new session on “Advancing your career” to learn about leadership and people skills, and how to exercise those skills and plan strategically to develop and establish a successful career in academia and industry.
  • A new session on “Commercialization of life innovation” to learn about technology transfer, the role of venture capital, and more about entrepreneurship.
  • Academic panelists from the U.S. to share their experience in research and career path in Academia.
  • Explore and build your career path in biotech or pharma by connecting with people from diverse fields.
  • Meet researchers from Academia Sinica. You may submit your CV to be considered in 1-on-1 setting.
  • Roundtable lunch with panelists
The annual meeting aims to provide platforms for interactions among young professionals, postdocs and students to share experiences and learn insight in diverse bio-related career paths.

The Summit invite you to attend the upcoming Young Health Innovators Forum 2017 (YHIF2017) Boston competition, which will be held at Harvard T.H. Chan School of Public Health on August 5 from 12:00 pm to 5:00 pm.

As an important part of the Summit, YHIF aims at helping young health innovators address unmet healthcare needs with innovative technologies and business models. This year, 12 teams will present their projects, which cover digital health, pharmacy, biotech, and other healthcare-related subjects. We will invite four finalists to Beijing to present their ideas in front of hundreds of hospital executives, pharmaceutical gurus, and investors.

We believe this is a great chance for you to catch up with latest healthcare investment hotspots, as well as meet many young healthcare professionals. You can find more details about the event on our website and get the free tickets of YHIF2017 by registering here. We look forward to seeing you this Saturday!
About U.S.-China Health Summit
The U.S.-China Health Summit is dedicated to the advancement of global health by promoting the exchange of knowledge, ideas, and experiences of healthcare leaders from the U.S., China, and other countries through high-level strategic dialogues, leadership development programs, and applied research. Click here to learn more about us.
The 7th U.S.-China Health Summit (the Summit) is coming in September. As the organizing committee, we invite you to attend the first part of the Summit, which will be held on September 15, 2017 in Boston.
Since its inauguration in 2011, the Summit has been dedicated to promoting exchange of knowledge, ideas and experiences of healthcare leaders from the U.S., China, and other countries. Last year, over 200 scholars, 300 company representatives, 400 government officials and 1,100 hospital executives from both the U.S. and China attended the 6th Summit, discussing a variety of academy, policy and investment topics in 10 forums.
This year, we are still boosting that communication and collaboration. 2017 is a unique year, marking both the inception of China’s implementation of the Healthy China 2030 Plan and the beginning of President Trump’s new Administration. Since the annual Summit has been held alternately in the U.S. and China since 2011, and by tradition this year’s Summit shall be held in the U.S., this year we will have a Boston Part (Part 1) of the Summit on September 15. In addition, we will organize a Beijing Part (Part 2) of the Summit on September 23, following the Centennial Celebration of Peking Union Medical College (PUMC)
Themed “Megatrends in Health and Healthcare,” this year’s Summit will focus on: 1) the changing world and emerging health challenges; 2) megatrends in health and medical sciences and technology; and 3) megatrends in healthcare service innovation. Confirmed keynote speakers of the Boston Part include:
Mark Elliott, Vice Provost for International Affair, Harvard University
Arthur Kleinman, Professor of Medical Anthropology in the Department of Social Medicine, Harvard Medical School
Ezra Vogel, Henry Ford II Professor of the Social Sciences Emeritus, Harvard University
Robert Huckman, Albert J. Weatherhead III Professor of Business Administration, Harvard Business School
The list may be subject to slight change. Tickets are sold on a first come, first served basis, and we are offering early bird discounts for registration before August 21.
For more information about this year’s or past Summit, please refer to our website: www.uschinahealthsummit.org, or email us at: info@uschinahealthsummit.org. We look forward to witnessing with you how healthcare leaders from the U.S., China, and other countries are moving forward together

7/27: US-CHINA Healthcare Transaction Lessons

2017-07-14 Xiaoyang 斐药圈
Topic:
US-CHINA Healthcare Transaction Lessons 

Date:
July 27th, Thursday from 7:00pm to 9:00pm

On Thursday, July 27th, San Francisco Healthcare Drinks, CABS, and ChinaMed Capital will host a talk by Carey Chern, General Counsel of SciClone entitled 'Lessons Learned from US-CHINA Cross Border Healthcare Transactions'. Chinese life sciences companies and Investors (e.g., PE and venture capital firms) are interested in doing transactions with US companies, including M&A, licensing and other commercial transactions.  Carey will provide his legal perspective on US companies entering into transactions with Chinese entities.

About Carey

Carey Chern joined SciClone in October 2016 and serves as General Counsel and Corporate Secretary, as well as SciClone's Chief Compliance Officer. Prior to joining SciClone, from 2011 to 2016, Mr. Chern served in various roles at The Clorox Company covering healthcare matters. Prior to The Clorox Company, Mr. Chern served in various roles at Amgen Inc. Prior to Amgen, Mr. Chern served as an attorney in several large international law firms covering life sciences and corporate transactions matters. Mr. Chern earned a J.D. from Stanford Law School and his A.B. in Economics and Government from Harvard University.

Event Location:
1633 Old Bayshore Hwy, Suite 280, Burlingame, CA 94010.

Contact Us:
Brian Hakim: +1(415)-902-6510     
Clare Gu:+86-186-163-16925     

RSVP:
To RSVP, please send your full name and company name to 
Sanfrancisco@healthcaredrinks.com




斐药圈(ChinaMed Capital Group)
Symposium program can be found on our website: http://btbatw.org/2017

19th SAPA-NE AC Brochure



点击注册



Greetings from Conference Chair

Dear SAPA Members and Friends:

On behalf of the organizing committee, it is my great pleasure to welcome you to the 19th Annual Conference of the Sino-American Pharmaceutical Professionals Association New England (SAPA-NE). SAPA-NE is a non-profit organization founded in 1998 and currently serves more than 2000 pharmaceutical/biotech professionals. Our mission is to serve its members and foster their career development through conference/symposium/networking and to promote exchanges and collaboration across pharmaceutical/biotech industries and academics between China and the US.
Our annual conference is SAPA-NE’s most prestigious event. Every year we bring together leaders from academia and industry, investors and entrepreneurs from around the world to share the cutting-edge discovery, exciting clinical development, and experiences and trends in business and career in life sciences. The theme of this year’s conference is "Convergence: Transformation of Life Sciences in Boston".
Boston is now recognized as the epicenter of innovation for both biologics and small molecules R&D in the world. More than 400 large and small biopharmaceutical companies have established headquarters or research centers here, plus many world-leading hospitals and prestigious universities, among them are Novartis, Pfizer, Sanofi, Biogen, Merck, Astra-Zeneca, AbbVie, Bristol-Myers Squibb, Takeda, Shire, EMD Serono, J&J and Bayer etc., as well as numerous small innovative companies. It’s difficult to fathom that this healthy and thriving ecosystem has not always been here. It started almost 10 years ago deep in the financial crisis that affected global economy. The Life Science Initiative enlisted the input and resources from government agencies, industry leaders, academic institutions, venture capitalists, and law firms. What we have witnessed since is an unprecedented growth in translating research discovery into therapeutic development. The game-changing immunotherapy in cancer treatment, the potential applications of genome editing technology such as CRISPR-Cas9, are just a couple of many areas that local companies are working on. This is the golden area of life sciences innovation, and Boston is the place where it all happens.
There are multi-national pharmaceutical companies overcoming cultural and organizational challenges to locate research centers in Boston area. There are local startups successfully raising capital when the overall trend is less than ideal. There are talented scientists helping accelerate the R&D process by crossing over between academia and industry. Those are the reason behind the theme for this year’s annual conference, to celebrate what makes Boston uniquely attractive to life sciences – the convergence of all the essential elements needed for transformation. This full day event will include plenary sessions, panel discussion, and a dinner reception. Biopharma industry senior executives, Chinese returnee entrepreneurs, and other experts will share their visions on scientific innovation, high-tech entrepreneurship, new trends in R&D globalization and strategies. Local and Chinese companies will bring a variety of job opportunities and set booths to recruit talents.

This year’s annual conference dinner reception is generously supported by our Diamond Partner, Greenberg Traurig, LLC, which is celebrating its 50th Anniversary. A keynote speech titled “Convergence of Law and Biopharma” will be given by Dr. Fang Xie, co-lead of its Biotechnology and Pharmaceutical Group.

Finally, I would like to express my most sincere gratitude towards all the members of the conference organizing committee for their outstanding work and unparalleled dedication in making this event possible. I am also grateful for all our valued sponsors for their generous and continued support. Everybody is welcome to join SAPA-NE and together we build an even stronger community. Thank you!

Sincerely yours,


Larry Cai, MBA, MS.
SAPA-NE 19th Annual Conference Chair
SAPA-NE President Elect 2016-2017



Conference Program
8:00 – 9:00
Registration and Breakfast
Opening Remarks
9:00 – 9:10
Mr. Larry Cai, Conference Chair, SAPA-NE President-Elect
Hon. Deval Patrick, Governor, Massachusetts (2007-2015)
Mr. Jijun Xing, Counselor of S&T, Consulate General of P. R. China
Session 1: Cutting Edge of Biomedical Innovation in Boston
Chairs: Drs. Jun Johnny Yang, Xingfeng Bao, Kejie Li, Lin Lin, Jing Tong
9:10 – 9:45
Dr. Andy Plump, Chief Medical and Scientific Officer, Takeda
“The Future of Drug Discovery: Innovation-driven Research & Development at Takeda”
9:45 – 10:20
Dr. Richard Murray, CEO and President, Jounce Therapeutics
“Immunology meets oncology: breakthroughs in immunotherapy”
10:20 – 10:50
Coffee Break and Exhibition
10:50 – 11:25
Dr. Sven Ante “Bill” Lundberg, CSO, CRISPR Therapeutics
“Bringing CRISPR Therapeutics to the Clinic”
11:25 – 11:50
Dr. Luhan Yang, CSO, eGenesis
“Gene Editing to Transform Xenotransplantation”
11:50 – 12:10
Dr. James Yang, President/CEO of Abpro China
“Fast Road Map for Biologic R&D”
12:10 – 1:00
Lunch and Exhibition
Session 2: Collaborations and Opportunities Across the Ocean
Chairs: Drs. Mangeng Cheng, Dapeng Chen, Haishan Li, and Bing Ma
1:00 – 1:20
Dr. Rich Soll, SVP & Head of International Discovery Services Unit (IDSU)
Enter the Era of Big Data, Deep Learning, and Artificial Intelligence: Capitalizing on a Transformative Opportunity for Drug Discovery”
1:20 – 1:40
Dr. Shidong Jia, Founder & CEO, Predicine Holdings Ltd.
“Precision medicine: clinical application of liquid biopsies in cancer”
1:40 – 2:00
Chaoshe Guo, Ph.D., Vice President and Senior R&D Director, Beijing Biocytogen Co.,Ltd
“Humanized immune checkpoint mouse models and in vivo efficacy studies of I/O drugs”
2:00 – 2:20
Ms. Jane Li, Co-founder, AF Recruiting
“Landscape of Healthcare Job Market in China”
Panel Forum: Collaborations and Opportunities Across the Ocean
Chairs: Drs. Tianxiao Sun and QiYing Hu
2:20 – 3:20
Dr. Shaohui Huang, Zhongshan Tsuihang New District
Dr. Ruhong Jiang, Applied Stemcell
Dr. Jinbo Lee, Scilligence
Dr. John MacDougall, CrownBio
Dr. Weimin Tang, Hengrui Therapeutics Inc.
Dr. Tony Xie, Xiyu Investment Company
3:20 – 3:50
Coffee Break and Exhibition
Session 3: Entrepreneurship and Global Leadership in Biomedical Sciences
Chairs: Mr. Larry Cai, Drs. Guiqing Liang and Jianzhu Chen
3:50 – 4:20
Dr. Lijun Wu, Entrepreneur-in-Residence, Atlas Venture, former SVP, Preclinical & Early Clinical Development, Delinia, Inc
“From Seed to Exit in 15 Months: The Delinia Story”
4:20 – 4:50
Dr. Yinxiang Wang, Chairman, Beijing JacoBio Pharmaceuticals, former CEO & CSO, Zhejiang Betta Pharmaceuticals
“Challenges and Strategies of Innovative Drug R&D in China”
4:50 – 5:25
Dr. Yong-Jun Liu, Head of Research, Global R&D, Sanofi
“Follow the Science and Capture the Opportunities”
5:25 – 5:30
Closing Remark: Dr. Jiang Long, President of SAPA-NE
SAPA-NE 19th Annual Conference Dinner Reception (Ticket Required)
Sponsored by Greenberg & Traurig, LLP
(Location: Samberg Conference Center, 50 Memorial Drive, Cambridge MA)
Chair: Dr. Jiang Long, President of SAPA-NE
6:00 – 6:30

6:30 – 6:35


6:35 – 6:45



6:45 – 7:00



7:00 – 7:10


7:10 – 9:00
GT HomeNetworking

Welcome Remarks
Dr. Jiang Long, President of SAPA-NE

Keynote Speech
Dr. Fang Xie, Co-lead, Global Life Science, Greenburg Traurig, LLP
“Convergence of Law and Biopharma”

SAPA-NE Cooperate Service Award/Service Award Presentations
Dr. Jiang Long and Mr. Larry Cai/ Drs. Bingli Ma, Mark Lin, Xiaotian Zhong, Min Chen

SAPA-NE High School Excellence Scholarship Presentation
Drs. Huo Li and Guiqing Liang

Dinner/Networking

Opening Remark

Honorable Deval Patrick
Governor, Commonwealth of Massachusetts (2007-2015)

Deval 2.jpg






Jijun Xing, Ph.D.
Science and Technology Counselor, Chinese Consulate-General in New York

邢继俊(简历照)








Session 1: Cutting Edge of Biomedical Innovation in Boston

http://www.takeda.us/images/usr/default/header_logo_ci.jpg
Andy Plump, MD, PhD Chief Medical and Scientific Officer, Takeda Pharmaceuticals
Presentation title: The Future of Drug Discovery: Innovation-driven Research & Development at Takeda





Richard Murray, Ph.D., Chief Executive Officer and President
Presentation title: Immunology meets oncology: breakthroughs in immunotherapy




Logo
Dr. Sven Ante “Bill” Lundberg, Chief Scientific Officer, CRISPR Therapeutics
Presentation title: Bringing CRISPR Therapeutics to the Clinic






http://www.egenesisbio.com/uploads/2/8/6/4/28647375/1472768483.png
LUHAN YANG, Ph.D., Co-Founder and CSO
Presentation title: “Gene Editing to Transform Xenotransplantation






James Yang, Ph.D., President and CEO, Abpro-China
Presentation title: “Fast Road Map for Biologic R&D






Session 2: Collaborations and Opportunities Across the Ocean

http://www.wuxiapptec.com/images/logo1.png
Dr. Rich Soll, SVP & Head of International Discovery Services Unit (IDSU)
Presentation title: Enter the Era of Big Data, Deep Learning, and Artificial Intelligence: Capitalizing on a Transformative Opportunity for Drug Discovery






http://www.predicine.org/uploads/4/6/3/9/46396713/logo-vision.png
Shidong Jia, Ph.D., Founder & CEO, Predicine Holdings Ltd
Displaying image1.JPGPresentation title: “Precision medicine: clinical application of liquid biopsies in cancer”






Chaoshe Guo, Ph.D., Vice President and Senior R&D Director, Beijing Biocytogen Co.,Ltd
Presentation Title: Humanized immune checkpoint mouse models and in vivo efficacy studies of I/O drugs







Ms. Jane Li,
Co-founder of AF Recruiting
Presentation title: Landscape of Healthcare Job Market in China




Panel Forum: Collaborative Innovation and Partnership




Shaohui Huang, Ph.D., Business Consultant, Zhongshan Tsuihang New District; President & Co-Founder, LightEdge Technologies, Ltd.; Professor, Institute of Biophysics, Chinese Academy of Sciences







Applied StemCell
Ruhong Jiang, Ph.D.,
Co-founder, President and CEO, Applied StemCell, Inc.





Jinbo Lee, Ph.D., Co-founder and Chief Scientific Officer of Scilligence Corporation






John MacDougall, Ph.D., Director of Scientific Engagement, CrownBio




Image result for jiangsu hengrui medicine
Weimin Tang, Ph.D., Head of BD, Jiangsu Hengrui Medicine Co.







logo.png
王利春,科伦药物研究院常务副院长,国家大容量注射剂工程技术研究中心主任







Mr. Shuijiang Zhou, Founder, Xiyu Investment Company



Session 3: Entrepreneurship and Global Leadership in Biomedical Sciences

https://atlasventure.com/wp-content/uploads/Delinia.png
Lijun Wu, Ph.D., Entrepreneur-in-Residence, Atlas Venture, former SVP, Preclinical & Early Clinical Development, Delinia, Inc
Presentation title: “From Seed to Exit in 15 Months: The Delinia Story”





Beijing Jacobio Pharmaceuticals Co.,Ltd
Yinxiang Wang, Ph.D., Chairman, Beijing JacoBio Pharmaceuticals, former CEO & CSO, Betta Pharmaceuticals
Presentation title: Challenges and Strategies of Innovative Drug R&D in China





Logo
Dr. Yong-Jun Liu, Head of Research, Global R&D, Sanofi
 Presentation title: Follow the Science and Capture the Opportunities



Dinner Reception Keynote Speech


Dinner Keynote Speaker:
Fang Xie, Ph.D.
Of Counsel, Co-lead, Global Life Sciences, Greenberg Traurig, LLP, Boston

Presentation title: The Convergence of Law and Biopharma”









Diamond Partner

https://pbs.twimg.com/profile_images/819255504463478784/7PLlkNxG.jpg

Platinum Partner

http://www.wuxiapptec.com/images/logo1.png


Media Partner


Gold Partner


http://www.predicine.org/uploads/4/6/3/9/46396713/logo-vision.png


Silver Partner

Applied StemCell https://www.bms.com/content/dam/bms/us/en-us/downloads/BMS-logo.jpg
Image result for jiangsu hengrui medicine logo.png http://www.takeda.us/images/usr/default/header_logo_ci.jpg
https://vcanbioctbblog.files.wordpress.com/2017/02/cropped-20160816015810429.jpg?w=300


Event Partner
http://www.aberjonalabs.com/images/header.jpg Achemtek


Logo Image result





Beijing Jacobio Pharmaceuticals Co.,Ltd
China CRO Company,Preclinical research services
Selleck Chemicals Logo https://www.wyzerbio.com/wiser/image/top-banner.jpg

Directions to Tang Center
Address: Tang Centrer, 70 Memorial Drive, Cambridge, MA 02142
Due to construction activities in the area, many parking lots are no longer available. It is highly recommended to carpool or to take public transportation to the event. The closest subway station (T) is Kendall Square stop (Red-line).
Parking (important notice!)
There is a small parking lot (E51 lot) for Tang Center with limited number of spaces shown in the map below. Also, there are several public parking lots or garages in Kendall Square area in walking distance to Tang Center.
One closest parking garage (3 blocks walking distance to Tang Center) is shown below:
Kendall Square South Garage ($11 on Saturday), 350 Kendall St, Cambridge, MA 02142

点击注册

19th SAPA-NE Annual Conference

         June 17, 2017@MIT

        广  欢  阵  药

        积  迎  容  协

        人  参  强  年

        脉  加  大  会

Registration link:

http://www.sapa-neweb.org/AC2017.php


Registration to 19th SAPA-NE Annual Conference 2017

19th SAPA-NE Annual Conference 2017


Date: 9:00 am - 6:00 pm (Conference), Saturday, Jun 17th, 2017
Dinner Event: 6:30 pm - 9:30 pm, Saturday, Jun 17th, 2017
Location: MIT Sloan School of Management, Tang Center, Wong Auditorium, Cambridge, MA

Registration:
Free for all active SAPA-NE members and MIT students
$15 for students and postdoctoral fellows
$30 for all other participants
Thank you for your donation to SAPA-NE. Please fill in all the information.
This donation is not refundable.Thank you.


Confirmed Speakers:

Andrew “Andy” Plump, M.D., Ph.D., Chief Medical and Scientific Officer, Takeda 



Yong-Jun Liu, Ph.D., Head of Research, Global R&D, Sanofi



Richard Murray, Ph.D., Chief Executive Officer and President, Jounce Therapeutics 



Sven Ante “Bill” Lundberg, Ph.D., Chief Scientific Officer, CRISPR Therapeutics 



Yinxiang Wang, Ph.D., Chief Executive Officer, Jacobio Pharmaceuticals, Co-found of Betta Pharma 



Lijun Wu, Ph.D., Entrepreneur-in-Residence, Atlas Ventures, SVP at Delinia (now Celgene) 



Luhan Yang, Ph.D., Co-founder and Chief Scientific Officer, eGenesis 



James (Jianguo) Yang, Ph.D., President & CEO, Abpro-China Shidong Jia, Ph.D., Founder & CEO, Predicine Holdings Ltd

哈佛医学院中医药论坛
Traditional Chinese Medicine Forum-HMS

Time: 9:00am-6:00pm Sunday August 6, 2017

Place: Harvard Medical School, McLean Hospital, 115 Mill Street, Belmont,

MA 02478 FRANCIS de MARNEFFE (cafeteria)

Parking: Free 
CEUs (Continue Education Credit): 9 credits

Fee (lunch included): 

Need 9 CEU Credits: $130 for MSCM members; $180 for non-members

Free for Dr. Lee’s group, Harvard Faculty/Fellow (Please contact us, reservation needed)


Sponsored: Massachusetts Society of Chinese Medicine (MSCM)

Alternative Medicine Center, McLean Hospital, HMS
Program

9:00-9:15am Registration

9:15-12:30pm “针灸治疗花粉过敏症临床观察及特效针法演示”
Acupuncture for the treatment of seasonal allergies 
& Special techniques Demo

12:30-2:00pm Lunch & discussion

2:00pm-6:00pm “常用针刺手法实际操作技巧临床应用研究”
Clinical use of acupuncture techniques and Demo

Speaker: 纽约著名的中医专家林榕生博士, Dr. Rongsheng Lin


Contact 
Call Dr. Li 617 323 7809 or 
Email:Johnzhang999@gmail.com
一 简介: 林榕生: 纽约著名中医专家,中医针灸博士,主任医师,现为世界中医药学会联合会副主席、国际中医药专业高级技术职称评审委员会委员、世中联骨伤科、外治方法研究及穴位埋线等专业委员会副会长;世界针灸学会联合会执委、世针联中医针灸传承工作委员会副主任委员、美国中医药学会董事局主席,福建中医药大学美国校友会会长,美国大纽约中医针灸学会总顾问、全美华裔中医组织联合会副主席,国际中医药联盟美容养生专家委员会副主任委员,福建中医药大学等多所大学以及中国全军针灸培训中心客座教授,联合国教科文组织人类非物质文化遗产代表作名录中医针灸代表性传承人张缙教授亲传入室弟子。

二,上午讨论的题目:“针灸治疗花粉过敏症临床观察及特效针法演示”

三,下午讨论的题目:“常用针刺手法实常用针刺手法实际操作技巧临床应用研究”


CABA美中生物医药协会2017年会暨十周年庆典召开在即

 2017-04-11 Jo Lee CABA

“Boston BioForum 2017”
CABA10th Annual Conference
Coming Soon!!!
🏨Boston Marriott Newton
📍2345 Commonwealth Ave, Newton, MA 02466
🕙10:00 AM to 6:00 PM on Saturday, May 6, 2017.


















SPEAKERS

Gordon Freeman

Professor at Harvard University

Carmen Bozic, MD
Carmen Bozic MD is Senior Vice President of Global Development at Biogen, accountable for developing, obtaining and maintaining regulatory approval of therapies in Biogen’s therapeutic focus areas of Neurodegenerative and Rare Diseases. Dr. Bozic is an experienced drug development leader with 18 years of progressively increasing responsibilities in the biopharmaceutical industry.
Kenneth I Kaitin, Ph.D.
Dr. Kaitin is Professor of Medicine and Director of the Tufts Center for the Study of Drug Development at Tufts University School of Medicine. Dr. Kaitin alsoholds appointments as Advisory Professor at Shanghai Medical College of Fudan University in China; Visiting Executive at the Tuck School of Business at Dartmouth College; and faculty of the European Center for Pharmaceutical Medicine at the University of Basel.
Ken LeClair, Ph.D.
Ken LeClair received his undergraduate degree from BowdoinCollege and a Ph.D. in Immunobiology from Yale University.
He did a postdoc at the MIT Center for Cancer Research andhad an academic appointment as Assistant Professor of Medicine in theImmunology Division of the Beth Israel Deaconess Medical Center at the Harvard Medical School.
He joined Editas Medicine late in 2016 and is working to help bring CRISPR-based therapies to the clinic and to market.
Samarth Kulkarni, Ph.D.
Samarth(Sam) Kulkarni is the Chief Business Officer of CRISPR Therapeutics since 2015.  At CRISPR, Sam is responsible for Corporate Strategy, Business Development, and Investor Relations. Sam has significant expertise in strategy and operations in biotech and a wide range of related cutting-edge therapeutic technologies. 
Xinyu Weng, Ph.D.
Weng, Xinyu, Ph.D, is First Secretary of the Embassy of the People’s Republic of China to the United States of America. As the primary point ofcontact for China Food and Drug Administration (CFDA) in the U.S., Dr. Weng is committed to strengthening bilateral food and drug regulatory cooperation between China and the U.S., and reaching out to the U.S. food and drug industry.
Lynn Yang, MBA
Lynn Yang, focusing on healthcare investment. Prior to joining Sequoia Capital in May,2015, Lynn worked at Legend Capitalhealthcare team. Lynn accomplished investment deals in different area of healthcare industry. Before setting her foot in venture capital, Lynn worked as business development manager in Johnson & Johnson and product managerat GE Healthcare.  
Mrs. Yang holds a MBA from Duke University and Master of Clinical Science from Huazhong Technology University.
Jason Fisherman, MD, MBA
Jason is an investor in medical innovation, drug developer, and company founder. He has worked to build life science companies as a managing director at the global private equity firm Advent International and subsequently as co- founder of the venture spin-out Synthesis Capital. Jason has funded more than thirty companies that have brought over ten new products to market.
James (Jianguo) Yang, Ph.D.
Dr. James (Jianguo) Yang has over 20-year extensive experience in biopharma industry. Currently, Dr. Yang is President / CEO Abpro-China. Before joining Abpro, Dr. Yang was CSO / VP Biologics in Qilu Pharmaceuticals, and also had scientific leadership positions in Abbott Lab Pharma Division, MedImmune /Astra Zeneca, and Genzyme / Sanofi.

Junzhi (John) Yao, Ph.D.
Dr. Junzhi (John) Yao received his PhD degree in chemistry from Wuhan University. He joined Medicure Inc. in Winnipeg, Canada as a Research Scientist conducting drug discovery research for cardiovascular diseases and stroke.

In 2009, Dr. Yao co-founded TC Scientific Inc. in Edmonton, Alberta, Canada, which has become one of the top CROs in Canada.
Hui Cai, Ph.D.
Dr. Hui Cai joined WuXi AppTec in 2009 as Vice President of Business Development, and is currently Vice President of Corporate Alliances,and Head of PR and Corporate Communications.
Prior to WuXi, Dr. Cai spent 10 years at Johnson& Johnson Pharmaceutical Research and Development leading multiple drug discovery programs in the therapeutic areas of inflammation and autoimmunediseases.



















Agenda

09:00 - 10:00 am      Registration / Social and Networking
10:00 - 10:05 am      Opening Remarks, Conference Chair
10:05 - 10:15 am      Introduction of CABA, President, CABA
Featured Speaker
10:15 - 11:00 am       Kenneth I. Kaitin,Ph.D., “The Global Landscape for Pharmaceutical R&D: Current Trends -Future Opportunities”
Session I -Immunotherapy: for the Cure ofCancer
11:00 - 11:35 am       Samarth Kulkarni,Ph.D. “CRISPR-based Therapeutics:  Making it a Reality in Asian Markets”
11:35 - 12:10 pm       Ken LéClair, “Development of Cell and Gene-edited Products”
LUNCH AND VENDOR SHOW: 12:10 - 1:30 pm (LunchProvided on Site)
LUNCHOEN PRESENTATION
12:45 - 1:15 pm  TC Scientific Presentation, John Yao, "A CRO's View of the Pharma Landscape"
SESSION II – Innovation,Investment, and Entrepreneurship
1:30 - 2:05 pm          Hui Cai, Ph.D. Wuxi (TBD ,)
2:05 - 2:40 pm          James Yang, Ph.D. “StrategicPartnership for Success in Biologics
2:40 - 3:15 pm           Lynn Yang, MBA, Sequoia Capital “Sequoia China HealthcareInvestment Strategy”
3:15 - 3:50 pm           COFFEE BREAK AND VENDOR SHOW
SESSION III - CFDA Regulatory reform and Innovation for the benefit ofPatients           
3:50 - 4:25 pm           Jason Fisherman, M.D.(TBD)
4:25 - 5:00 pm           XinYu Weng, Ph.D; MBA. “Overview onCFDA Drug Regulatory Reform”    
5:00 - 5:35 pm           Carmen Bozic, M.D. SVP GlobalDevelop. “Innovations in Intrathecal Antisense Oligonucleotide Therapy forNeurological Diseases”
5:35 - 6:00 pm          Closing Remarks and Networking
Registration:
Link: http://caba-annualmeeting-2017.eventdove.com
也可点击文末“阅读原文”或长按以下图片提取二维码直达注册页面。
同写意论坛第59期活动

中国在研药品的FDA法规注册之路

时   间
2017年6月3-4日
地   点
苏州·独墅湖世尊酒店
主   办
同写意新药英才俱乐部
承   办
北京梓潭管理咨询有限公司
协  办
复旦大学药学院
Humphries Pharmaceutical Consulting, LLC
博瑞生物医药(苏州)股份有限公司
新药创始人俱乐部
支持单位
海思科药业
杭州和泽医药科技有限公司
支持媒体

HPC药闻药事、米内网、新浪医药、GBI、药事纵横、健点子ihealth、汤森路透、药智网、药物简讯、苏比亚、易贸医疗、药渡、医药信息新药开发群、医药研发社交平台、药物临床试验网、投壶网、火石创造、贝壳社、汇聚南药、当代医生、中睿医药评论、中国医药报、医药经济报、Insight数据库、新药汇、药物一致性评价、药研、药研汇、洛施德GMP咨询

HKS Science + Innovation Diplomacy Symposium
The HKS Science + Innovation Diplomacy Symposium aims to put a spotlight on the intersection of Science and innovation with diplomacy and how these two elements act as drivers for solutions to foreign policy challenges.
The Science + Innovation Diplomacy Symposium will provide a space for a trilateral exchange between Academia, Policy makers and the Private Sector to discuss “common ground” where science and innovation can be used as a bridge between governments and people.
Saturday, April 15, 2017 | 9:00AM - 3:30PM
Starr Auditorium, 5th Floor, Belfer Building
79 John F. Kennedy Street
Cambridge, MA, 02138
This event is free and open to the public. As space is limited for this event, RSVPs will be accepted on a first come, first served basis.

At the Harvard T.H. Chan School of Public Health on Friday, April 7th for the 2017 Health Equity & Leadership Conference themed “Advocacy and Leadership for Health Equity.”

Closing keynote: Dr. Elisa Choi, Chairperson of the Commonwealth of MA Asian American Commission

Tickets are FREE and open to all. PLEASE REGISTER in advance through Eventbrite to ensure entry, as space is limited. Lunch and refreshments are included!

REGISTER HERE: http://bit.ly/2n5Raly

HEAL was formed in 2012 by a group of students at the Harvard T.H. Chan School of Public Health dedicated to generating discourse and action to resolve issues related to health inequities in the Boston and Cambridge communities. This year we aim to expand our scope to discuss how we can address health equity in a new administration from grassroots organizing to lobbying policymakers. We seek to foster a conversation between community members, students, and faculty about the causes of inequities, the role of community organizations in serving vulnerable populations, and innovative solutions for a more equitable future.

Featured speakers and panelists include:
* Thaddeus Miles, Director of Community Services at MassHousing)
* Dr. Benjamin Cook, Director of the Health Equity Research Lab and the Center for Multicultural Mental Health Research
* Eva Stahl, Director at Community Catalyst Children's Health Project
* Ashley Slay, Boston Area Rape Crisis Center
* Irvienne Goldson, Deputy Director of ABCD Health Services
* Dr. Nancy Oriol and Jennifer Bennet, Executive Director of The Family Van
and more to be announced!

See below for a tentative conference agenda:
*subject to changes*

8:30am - 9:30am- Registration & Breakfast
9:30am -10:20am- Opening Remarks
10:30am -12:20pm- Panels
- Panel #1 - Advocating for Health Equity: Translating Research & Policy into Action
- Panel #2 - Community-Based Approaches to Health Equity
12:30-1:30PM- Lunch
1:30pm-2:20pm- Workshops Session #1
- Grassroots Organizing
- Advocating for Health Equity in a Clinical Setting
- Negotiation and Conflict Resolution
2:30pm-3:20pm- Workshop Session 2:
- Negotiation and Conflict Resolution
- Public Speaking
- Social Entrepreneurship and Innovation
- Grassroots Organizing
3:30pm-4:30pm Closing Keynote


哈佛医学院中医药论坛
Traditional Chinese Medicine Forum-HMS

Time: 9:00am-5:00pm Sunday May 21, 2017
Place: McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA 02478 FRANCIS de MARNEFFE (cafeteria)
Parking: Free 

CEUs (Continue Education Credit): 9 credits
Fee (lunch included): 
Need 8 CEU Credits: $90 for MSCM members; $120 for non-members
No CEU, Free for Dr. Lee’s group, Harvard employee (reservation needed)
Sponsored: Massachusetts Society of Chinese Medicine (MSCM)
Alternative Medicine Center, McLean Hospital, HMS

Program

9:00-9:15am Registration
9:15-12:00pm Integration of Stretching motion and Tuina with Acupuncture
导引运动,推拿与针灸的整合应用
12:00-1:30pm Lunch & discussion
1:30pm-5:00pm Holistic approach in treating neuroendocrine disorders
神经内分泌系统功能紊乱的中医与自然疗法
Speaker: Dr. Jing Liu, PhD, L.Ac


Contact 
Call Dr. Li 617 323 7809 or 
Email:Johnzhang999@gmail.com






Allurion Repays Massachusetts Life Sciences Center
Natick company has commercialized a gastric balloon technology
to combat obesity

Natick, MA - The Massachusetts Life Sciences Center (MLSC) and Natick-based Allurion Technologies announced today that the company, which was awarded a $750,000 Accelerator loan from the MLSC in 2011, has repaid the loan with interest after a successful funding round from private investors. Allurion’s repayment to the MLSC totaled $1,115,824.

Allurion’s flagship product is the Elipse™ gastric balloon, a procedureless™ medical device for weight loss.  The Elipse device comprises a balloon made of thin polymer film that is delivered in a 15-minute outpatient visit without need for anesthesia or surgery.  It is filled with water and resides in the stomach for four months, enabling weight loss which averages between 10% and 15% of starting weight.  At the end of therapy, a patented opening mechanism is automatically activated, allowing the device to empty and pass naturally.

At the time of the MLSC loan Allurion had three employees and was still developing its technology.  The company now has more than 20 Massachusetts-based employees.  Its product, which has not yet been approved by the FDA, is currently available in select weight loss centers in France, Italy, Belgium, Greece, the U.K., Spain, Kuwait, Saudi Arabia and Qatar, with plans for a U.S. clinical trial commencing in 2017.

Allurion has also served as a host company for the MLSC's Internship Challenge Program, hosting seven interns to date for which it has or will receive salary reimbursement through the MLSC. 

Allurion’s Chairman and CEO Jonathan Wecker said “the Accelerator loan from the MLSC did exactly what we needed – it accelerated our development and allowed us to build a case for traditional private investment.  We are grateful to the MLSC for its early confidence in our potential and are proud to have returned the funds, with interest, to the Commonwealth.”

“Our Accelerator Loan Program seeks to derisk promising earlystage companies and make them more attractive to private investors,” said Massachusetts Life Sciences Center President & CEO Travis McCready.  “We were pleased to provide early financial and workforce support to Allurion, both through our Accelerator Program and our Internship Challenge Program, as they built their company and developed this promising technology.  We look forward to seeing the ongoing positive impact that their technology will have on patients around the world.”

“The biotech sector is thriving across the state, and Allurion is a terrific example of innovation and entrepreneurship here in MetroWest,” said Senator Karen E. Spilka (D-Ashland). “This is a MLSC success story of a targeted investment in the life sciences cluster creating jobs and advancing critical technology. I look forward to continuing the state’s partnership with Allurion and other innovative life sciences companies in our community.”


“It is great to see that the MetroWest continues to be a leader in the research and development of life sciences,” said Representative David Linsky (D-Natick). “I look forward to the future projects that will come out of Allurion.”

SAPA-NE Career Development Symposium Career in Biotech Start-up and Entrepreneurship 
– Translating Research into Business, Ideas/Technology into Pipelines/Products 
MIT Maclaurin Building 4-370 182 Memorial Drive (Rear), Cambridge, MA 02138 
Saturday 1-6 PM, March 18, 2017 

Welcome to attend the 19th SAPA-NE Career Development Symposium on Saturday, March 18th, 2017 at MIT Maclaurin Building. The biopharma industry entrepreneurs and the experts in legal and venture capital will share their experience and perspective in successfully founding, managing or investing in biotech start-up(s) and overall insight and visions on scientific innovation and biotech entrepreneurship. The meeting will also provide the attendees an excellent opportunity to network with biopharmaceutical professionals around Boston area and to access some new job openings posted onsite. The Plenary Session Speakers include: Yi Zhang, Ph.D., a HHMI Investigator and Professor of HMS and BCH, and a co-founder of Epizyme Joy Alamgir, Entrepreneur, Founder, EVP and CSO of Consilience Software, A Xerox Company Chong Xu, Ph.D., Associate, F-Prime Capital Partners, Boston Ruhong Jiang, Ph.D., a co-founder, president and CEO of Applied Stem Cell Fang Xie, Ph.D., Of Counsel, Greenberg Traurig, LLP, Boston Follow by a panel discussion with all speakers plus Wei Zhao, Ph.D., Associate, Wuxi Healthcare Venture Online registration: http://sapa-neweb.org/CDS2017.php This event is free for SAPA-NE members and MIT students; $30 for non-members; $15 for students. (coorganizer MIT-CHIEF) SAPA-NE Career Development Symposium Organizing Committee 

U.S. Department of Homeland Security to Keynote at Biosurveillance Integration,
part of Biodefense World Summit

The national strategy for biosurveillance calls for a coordinated approach for threats to public health and safety, bringing together federal, state and local governments; private sector, nongovernmental organizations and international partners to enhance existing biosurveillance capabilities and develop new ones that provide decision makers and responders with the essential information to manage these threats. This strategy recognizes that a well-integrated national biosurveillance enterprise can save lives by providing essential information for better decision making at all levels. The Sixth Annual Biosurveillance Integration conference will address implementation strategies for the national strategy for biosurveillance identified core functions.
Luther LindlerBiosurveillance to Protect the Homeland
Luther Lindler, Ph.D., Senior Scientist (ST), Biological Programs, Chemical and Biological Defense Division Science and Technology Directorate, U.S. Department of Homeland Security
One of the Department of Homeland Security's (DHS) responsibilities is to protect the U.S. from a biological attack. The Science and Technology Directorate, through the Chemical and Biological Defense Division (CBD), has developed a Real Time Threat Awareness biosurveillance program that integrates information data streams with new detection technologies. This presentation will discuss the interest areas and progress DHS CBD is making toward building a 21st century biosurveillance program.

Dr. Lindler joined the DHS Science and Technology Directorate in October 2003 as a Senior Science Advisor. Dr. Lindler currently serves the Senior Scientist for biological programs within the chemical and biological defense division where he provides expertise to both DOD as well as DHS about current infectious disease threats from a global perspective. He currently serves on the Joint Influenza Surveillance Working Group for DOD, is the DOD representative to the Interagency Influenza Diagnostics Working Group, as well as senior advisor to DOD Health Affairs on technical diagnostic issues that affect force health protection. He currently manages several projects related to infectious disease for the AFHSC. The most notable is to bring forward deployed rapid molecular diagnostics to DOD forward deployed forces. He also serves on the National Biodefense Analysis and Countermeasures Center review committee for DHS S&T and has participated in the national Material Threat Assessment and Biological Risk Assessment programs. His first position within DHS was as the Science Advisor for the NBACC. He helped plan the NBACC forensics and threat characterization programs as well as the first DHS laboratory building on the Fort Detrick National Biodefense Campus. Before joining DHS, Dr. Lindler was a leader in the US Army Biodefense program. He was a principle investigator at the Walter Reed Army Institute of Research leading a team of professionals studying the pathogenesis of the plague bacterium. He served on the Army’s plague vaccine steering committee and the emerging threats steering committee within the Biodefense program. The peak of his career with the Army culminated with his senior editorship of the well-acclaimed Biodefense book entitled, “Biological Weapons Defense; Infectious Diseases and Counterbioterrorism.” Dr. Lindler was a postdoctoral fellow in the laboratory of Dr. Susan Straley at the University of Kentucky in Lexington from 1987 until 1989. Dr. Lindler received his Ph.D. in Microbiology from the Medical College of Virginia in 1987, his Masters of Science in Microbiology from Clemson University in 1981 and his Bachelor’s of Science in Medical Technology from Lenoir Rhyne College in North Carolina in 1978.






























WuXi NextCODE Appoints Hannes Smarason as CEO, John Long as CFO, and Alex Fowkes as COO

Appointments bolster global business expansion, operational integration and independent strategic development

NEWS PROVIDED BY
WuXi NextCODE 
Feb 28, 2017, 13:00 ET

SHANGHAICAMBRIDGE, Mass. and REYKJAVIK, IcelandFeb. 28, 2017 /PRNewswire/ -- WuXi NextCODE, a WuXi AppTec group company and the contract genomics organization enabling precision medicine worldwide, today announced that the company's chief operating officer Hannes Smarason has been appointed as the company's chief executive officer, and WuXi AppTec senior vice presidents John Long and Alex Fowkes have been named chief financial officer and chief operating officer, respectively.
"WuXi NextCODE is executing on its vision to enable anyone to use the genome to advance health and wellness worldwide," said Dr Ge Li, founder and chairman of WuXi AppTec group and chairman of WuXi NextCODE. "It is also positioning itself as the data management platform at the heart of the genomics revolution and what may become the world's largest data ecosystem. Hannes, John and Alex have the breadth of vision and proven executive capabilities to carry out this strategy and advance the company to the next level."































"This is an exciting time at WuXi NextCODE, as we work on leading projects in every facet of genomics and advance a global standard for the way genomic data is organized, mined and shared," said Mr Smarason. "John and Alex's leadership and experience in life sciences finance and operations, and in the recent independent listing of other WuXi AppTec companies, will be invaluable as we grow our business and forge our own strategic path. We are very pleased to have them join our team and offer them a warm welcome to WuXi NextCODE."
Hannes Smarason co-founded NextCODE Health in 2013 as a spinout from deCODE genetics. He oversaw NextCODE's acquisition by WuXi AppTec in 2015 and its merger with the WuXi Genome Center to create WuXi NextCODE. He served as COO until January 2017 and as CEO will lead the company's overall business and corporate strategy.
John Long has served as WuXi AppTec's senior vice president of finance since 2013. He was actively involved in WuXi AppTec's privatization from NYSE in 2015 and played important roles in WuXi AppTec's subsequent corporate restructuring, supporting WuXi Biologics's recent IPO filing process in Hong Kong as well as private placements in the China capital market. John has over twenty years' experience in financial management, investment and operations in the US, China and Singapore, and prior to joining WuXi AppTec served in senior roles at Willis Group, Tyco International and Lucent Technologies. In addition to finance and operations leadership, he will provide WuXi NextCODE with global expertise in governance, reporting, strategic planning, treasury and tax. John holds a bachelor's degree in economics from the University of International Business and Economics in Beijing and received his MBA from Wharton School of Business at University of Pennsylvania.
Alex Fowkes has twenty years experience in the life science industry in operations, business development, strategy and legal roles. He joined WuXi AppTec in 2012 initially to lead corporate development and then most recently serving as senior vice president of commercial operations. Prior to WuXi Alex served in a variety roles for Pfizer in the US, UK, Australia and China over 14 years.
About WuXi NextCODEWuXi NextCODE is a fully integrated global contract genomics organization. With offices in ShanghaiKendall Square in Cambridge, Massachusetts; and Reykjavik, Iceland, we offer comprehensive services that enable population, precision medicine, diagnostics and wellness initiatives and enterprises to use the genome to improve health around the world. Our capabilities span study design, sequencing, secondary analysis, storage, and interpretation and scalable analytics – all backed by the most proven and widely used technology for organizing, mining and sharing genome sequence data. We are also applying the same capabilities to advance a growing range of sequence-based tests and scans in China. WuXi NextCODE is a WuXi AppTec Group company. Visit us on the web at wuxinextcode.com.